Dec 25, 2024 · IKZF3 (IKAROS Family Zinc Finger 3) is a Protein Coding gene. Diseases associated with IKZF3 include Immunodeficiency 84 and Leukemia, Chronic Lymphocytic. Among its related pathways are IL2 signaling events mediated by STAT5 and 17q12 copy number variation syndrome.

Nov 5, 2020 · A hotspot mutation within the DNA-binding domain of IKZF3 (IKZF3-L162R) has been identified as a putative driver in chronic lymphocytic leukemia (CLL); however, its functional effects are unknown. We recently confirmed its role as a CLL driver in a B cell-restricted conditional knock-in model.

Mar 8, 2021 · Hotspot mutation of IKZF3 (IKZF3-L162R) has been identified as a putative driver of chronic lymphocytic leukemia (CLL), but its function remains unknown. Here, we demonstrate its driving role in CLL through a B cell-restricted conditional knockin mouse model.

Feb 8, 2025 · IKZF3 is a novel prognostic biomarker for head and neck squamous cell carcinoma: A study based on bioinformatics analysis. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.

In this study, we tested the hypothesis that IKZF3 is a transcriptional regulator of IL-10 using a human CD4 + T cell–only culture system. IL-10 + CD4 + T cells expressed the highest levels of IKZF3 both ex vivo and after activation compared with IL-10–CD4 + T cells.

Mar 3, 2023 · It has been demonstrated that the IKZF3 gene is dramatically correlated with hematopoietic malignancies such as multiple myeloma (MM) and chronic lymphocytic leukemia. IKZF3 protein expression levels were remarkably elevated in patients with MM stage III and correlated with higher OS.

Exons 4–6 harbor four zinc fingers that bind DNA and the C-terminus of exon 8 contains two zinc fingers that mediate homodimerization of Ikaros and heterodimerization with other Ikaros family members such as Aiolos (IKZF3).

Nov 2, 2024 · Title: IKZF3 is a novel prognostic biomarker for head and neck squamous cell carcinoma: A study based on bioinformatics analysis. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.

We here demonstrate that expression of Ikzf3 mutation skews B cell development, enhances B cell activation, and leads to leuke-mia development in elderly mice.

Mar 8, 2021 · Hotspot mutation of IKZF3 (IKZF3 -L162R) has been identified as a putative driver of chronic lymphocytic leukemia (CLL), but its function remains unknown. Here, we demonstrate its driving role in CLL through a B cell-restricted conditional knockin mouse model.